A Study to Compare the Effects of Improving the Carotid Artery Intima Media Thickness and Changing Lipid Levels by Cilostazol/Ginkgo Leaf Extract and Aspirin in Diabetic Peripheral Angiopathy.

Phase 4

Recruiting

• Conditions: Diabetic Peripheral Angiopathy
• Interventions: Drug: Renexin CR 200/160mg; Drug: Aspirin 100mg

• Registration Number: NCT05906199
• Lead Sponsor: SK Chemicals Co., Ltd.

Brief Summary

This study is to compare and evaluate the effect of improving the carotid IMT and lipid level of the Cilostazol/Ginkgo leaf extract group with the aspirin administrated group in patients with diabetic peripheral angiopathy.

Detailed Description

Not available

Study Timeline

• Study Start: 2021-07-28
• Status Verified: 2023-06
• Study First Submitted: 2023-06-07
• Study First Submitted QC: 2023-06-07
• Last Update Submitted: 2023-06-07
• Study First Posted: 2023-06-15
• Last Update Posted: 2023-06-15
• Primary Completion: 2023-07
• Study Completion: 2024-03

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Not provided

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Renexin CR 200/160mg	Renexin CR 200/160mg	Single oral administration of Renexin CR 200/160mg, QD
Aspirin 100mg	Aspirin 100mg	Single oral administration of Aspirin 100mg, QD

Primary Outcome Measures

Name	Time	Method
Changes in carotid IMT	24weeks, 48weeks	Changes in carotid IMT after 24weeks, 48weeks of administration compared to before administration of investigational product

Trial Locations

Locations (1)

SK chemicals; 🇰🇷 Seoul, Korea, Republic of